Many cancer patients diagnosed with late stage cancers exhibit CD8+ T cell hypo-responsiveness, which is primarily driven by nutrient competition between tumor and immune cells, limiting response to these kinds of therapies [47]. Here, CD8A is linked to neoplasm.